BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25371273)

  • 21. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
    Leone N; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):31-46. PubMed ID: 15756144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center.
    Forns X; Ampurdanès S; Sanchez-Tapias JM; Guilera M; Sans M; Sánchez-Fueyo A; Quintó L; Joya P; Bruguera M; Rodés J
    J Hepatol; 2001 Aug; 35(2):265-71. PubMed ID: 11580150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group.
    Okanoue T; Itoh Y; Minami M; Sakamoto S; Yasui K; Sakamoto M; Nishioji K; Murakami Y; Kashima K
    J Hepatol; 1999 Apr; 30(4):653-9. PubMed ID: 10207807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver fibrosis progression at autopsy in injecting drug users infected by hepatitis C: a longitudinal long-term cohort study.
    Kielland KB; Delaveris GJ; Rogde S; Eide TJ; Amundsen EJ; Dalgard O
    J Hepatol; 2014 Feb; 60(2):260-6. PubMed ID: 24096048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The usefulness of measuring liver stiffness by transient elastography for assessing hepatic fibrosis in patients with various chronic liver diseases.
    Tamano M; Kojima K; Akima T; Murohisa T; Hashimoto T; Uetake C; Sugaya T; Nakano M; Hiraishi H; Yoneda M
    Hepatogastroenterology; 2012 May; 59(115):826-30. PubMed ID: 22469726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
    Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
    Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The natural history of chronic hepatitis B: a retrospective study.
    Wu GC; Zhou WP; Zhao YR; Guo SH; Wang ZY; Zou SB; Zhang QH; Ren H; Huang AL; Zhang DF
    Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):566-70. PubMed ID: 14627521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C.
    Bonis PA; Tong MJ; Blatt LM; Conrad A; Griffith JL
    Am J Gastroenterol; 1999 Jun; 94(6):1605-12. PubMed ID: 10364032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of liver and spleen ADC measurements in the diagnosis and follow up of hepatic fibrosis in chronic liver disease.
    Tokgöz Ö; Unal I; Turgut GG; Yildiz S
    Acta Clin Belg; 2014 Dec; 69(6):426-32. PubMed ID: 25103596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.
    Halfon P; Bacq Y; De Muret A; Penaranda G; Bourliere M; Ouzan D; Tran A; Botta D; Renou C; Bréchot MC; Degott C; Paradis V
    J Hepatol; 2007 Mar; 46(3):395-402. PubMed ID: 17156890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Fibroscan on management of chronic viral hepatitis in clinical practice.
    Fransen van de Putte D; Blom R; van Soest H; Mundt M; Verveer C; Arends J; de Knegt RE; Mauser-Bunschoten E; van Erpecum K
    Ann Hepatol; 2011; 10(4):469-76. PubMed ID: 21911887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma: an emerging problem with hepatitis C.
    Jeffers L
    J Natl Med Assoc; 2000 Aug; 92(8):369-71. PubMed ID: 10992680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.
    Planas R; Ballesté B; Alvarez MA; Rivera M; Montoliu S; Galeras JA; Santos J; Coll S; Morillas RM; Solà R
    J Hepatol; 2004 May; 40(5):823-30. PubMed ID: 15094231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography.
    Masuzaki R; Tateishi R; Yoshida H; Goto E; Sato T; Ohki T; Imamura J; Goto T; Kanai F; Kato N; Ikeda H; Shiina S; Kawabe T; Omata M
    Hepatology; 2009 Jun; 49(6):1954-61. PubMed ID: 19434742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
    Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
    Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation.
    Cross TJ; Calvaruso V; Foxton MR; Manousou P; Quaglia A; Grillo F; Dhillon AP; Nolan J; Chang TP; O'Grady J; Heneghan MA; O'Beirne JP; Burroughs AK; Harrison PM
    J Viral Hepat; 2010 Sep; 17(9):640-9. PubMed ID: 19922441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.